Company intelligence / Profile preview

Trovis Pharmaceuticals

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Trovis Pharmaceuticals was a clinical-stage biotechnology company focused on the development of therapies for osteoarthritis and other musculoskeletal disorders. The company's primary asset was MIV-711 (formerly TV-02), a potent and selective small molecule inhibitor of cathepsin K, an enzyme involved in the breakdown of bone and cartilage. Trovis was acquired by the Swedish pharmaceutical company Medivir AB in 2014 to expand its portfolio into bone-related diseases. Following the acquisition, the lead candidate progressed into Phase 2 clinical trials to evaluate its potential as a disease-modifying osteoarthritis drug.

Therapeutic areas: Rheumatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Medivir

Beyond the preview

Go deeper on Trovis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trovis Pharmaceuticals.

Explore the full profile